Ellen Niederberger
Pharmazentrum Frankfurt/ZAFES
Institut für Klinische Pharmakologie
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
Theodor Stern Kai 7
Germany
Name/email consistency: high
- Analysis of NF-kappaB signaling pathways by proteomic approaches. Niederberger, E., Geisslinger, G. Expert. Rev. Proteomics (2010)
- The IKK-NF-kappaB pathway: a source for novel molecular drug targets in pain therapy? Niederberger, E., Geisslinger, G. FASEB J. (2008)
- Update on the pathobiology of neuropathic pain. Niederberger, E., Kühlein, H., Geisslinger, G. Expert. Rev. Proteomics (2008)
- Proteomics in neuropathic pain research. Niederberger, E., Geisslinger, G. Anesthesiology (2008)
- Impaired acute and inflammatory nociception in mice lacking the p50 subunit of NF-kappaB. Niederberger, E., Schmidtko, A., Gao, W., Kühlein, H., Ehnert, C., Geisslinger, G. Eur. J. Pharmacol. (2007)
- The impact of CREB and its phosphorylation at Ser142 on inflammatory nociception. Niederberger, E., Ehnert, C., Gao, W., Coste, O., Schmidtko, A., Popp, L., Gall, C., Korf, H.W., Tegeder, I., Geisslinger, G. Biochem. Biophys. Res. Commun. (2007)
- Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib. Niederberger, E., Manderscheid, C., Geisslinger, G. Biochem. Biophys. Res. Commun. (2006)
- The glutamate transporter GLAST is involved in spinal nociceptive processing. Niederberger, E., Schmidtko, A., Coste, O., Marian, C., Ehnert, C., Geisslinger, G. Biochem. Biophys. Res. Commun. (2006)
- Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Niederberger, E., Manderscheid, C., Grösch, S., Schmidt, H., Ehnert, C., Geisslinger, G. Biochem. Pharmacol. (2004)
- Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation. Niederberger, E., Tegeder, I., Schäfer, C., Seegel, M., Grösch, S., Geisslinger, G. J. Pharmacol. Exp. Ther. (2003)
